Life Sciences & Biotechnology
Title : | Understanding the post-acute COVID sequalae (PACs) of sARs-CoV-2 and its variants of concern (VoC). |
Area of research : | Life Sciences & Biotechnology |
Focus area : | COVID-19 |
Principal Investigator : | Dr. Zaigham Abbas Rizvi, Translational Health science And Technology Institute, Faridabad, Haryana |
Timeline Start Year : | 2024 |
Timeline End Year : | 2026 |
Contact info : | zaigham.abbas15@gmail.com |
Details
Executive Summary : | sARs-CoV2 has infected 5.5% of the global population, with a 1.4% mortality rate. Most cases develop pulmonary pathologies, including pneumonia, lung damage, and respiratory distress. However, a significant number of clinical cases result in extra-pulmonary pathologies affecting various organ systems. Host virus-entry factors, such as ACE2, TMPRss2, and NRP-1, lead to the spread of the virus to different organs and a host inflammatory response. This can lead to multiple-organ pathology associated with COVID-19. Post-acute COVID sequalae (PACs) is a group of symptoms that persist long after patients have been tested negative for sARs-CoV-2. The current study aims to address two important questions about PACs using a small animal model. The study will evaluate the tissue tropism of sARs-CoV-2 in infected animals, identifying subtle differences in viral load and expression patterns during peak infection and post-recovery phases. The findings will be of particular therapeutic relevance, providing future directs to design and evaluation of not only immediate pulmonary pathologies but also PACs. |
Total Budget (INR): | 27,10,800 |
Organizations involved